Astria Therapeutics
ATXS
ATXS was delisted on the 22nd of January, 2026.
27 hedge funds and large institutions have $24.9M invested in Astria Therapeutics in 2020 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 9 increasing their positions, 5 reducing their positions, and 9 closing their positions.
80% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 5
0% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 9
4% less funds holding
Funds holding: 28 → 27 (-1)
11.27% less ownership
Funds ownership: 44.86% → 33.59% (-11%)
20% less capital invested
Capital invested by funds: $31.3M → $24.9M (-$6.36M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$4.78M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.31M |
| 3 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
+$839K |
| 4 |
PHP
Parkman Healthcare Partners
Stamford,
Connecticut
|
+$803K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$284K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CA
Corriente Advisors
Fort Worth,
Texas
|
-$3.65M |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
-$617K |
| 3 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$578K |
| 4 |
JP Morgan Chase
New York
|
-$207K |
| 5 |
PTP
Platform Technology Partners
New York
|
-$195K |
ATXS Hedge Fund Activity: Q1 2020 in Review
27 of the 4,547 institutional investors tracked by Wall St. Rank reported a position in Astria Therapeutics (ATXS) for Q1 2020, worth a combined $24.9M — down 20% from $31.3M a quarter earlier.
Fund positioning in ATXS was balanced in Q1 2020: 9 funds opened new positions, 9 closed out, 9 added to existing stakes and 5 trimmed.
The largest buyer was Federated Hermes, adding an estimated $4.78M. The largest seller was Corriente Advisors, exiting entirely with an estimated $3.65M sold.
- 27 institutional investors held Astria Therapeutics (ATXS) as of Q1 2020, down from 28 in Q4 2019.
- Funds reported $24.9M of Astria Therapeutics stock for Q1 2020, down 20% quarter-over-quarter.
- 9 funds opened new Astria Therapeutics positions in Q1 2020 and 9 closed out, a net change of 0 holders.
- The largest Astria Therapeutics buyer in Q1 2020 was Federated Hermes, an estimated $4.78M added.
- The largest Astria Therapeutics seller in Q1 2020 was Corriente Advisors, an estimated $3.65M sold.
Based on aggregated 13F filings for Q1 2020.